TheraCell was issued U.S. Patent No. 9,636,436, “Compositions of and Methods for Cancellous Bone Matrix,” addressing its enhanced cancellous demineralized bone technology, ECS™.
ECS is a minimally-manipulated tissue product designed to combine the osteoinductivity of demineralized cortical bone powder with the osteoconductivity of demineralized cancellous bone. This patent extends TheraCell’s osteobiologic patent portfolio that also includes protection for Demineralized Bone Fiber.
Sources: TheraCell, Inc.; ORTHOWORLD Inc.
TheraCell was issued U.S. Patent No. 9,636,436, "Compositions of and Methods for Cancellous Bone Matrix," addressing its enhanced cancellous demineralized bone technology, ECS™.
ECS is a minimally-manipulated tissue product designed to combine the...
TheraCell was issued U.S. Patent No. 9,636,436, “Compositions of and Methods for Cancellous Bone Matrix,” addressing its enhanced cancellous demineralized bone technology, ECS™.
ECS is a minimally-manipulated tissue product designed to combine the osteoinductivity of demineralized cortical bone powder with the osteoconductivity of demineralized cancellous bone. This patent extends TheraCell’s osteobiologic patent portfolio that also includes protection for Demineralized Bone Fiber.
Sources: TheraCell, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
